Showing posts with label Menpausal Hormone Therapy( MHT). Show all posts
Showing posts with label Menpausal Hormone Therapy( MHT). Show all posts

Thursday, June 23, 2016

Plant based therapies and menopausal symptoms: A Systematic Review and Meta-analysis

According to data by North American Menopause Society (NAMS) about 6000 US women transition into menopause every day. With ever increasing life expectancy in western world (79.7 years) it is expected that by the year 2020 number of US women older than 51 will be 50 million and the corresponding statistics worldwide is 1.1Billion. [1]

Women who have undergone surgical menopause are more likely to use Hormone replacement therapy as compared to women with natural menopause. About 75% of women who undergo surgical menopause use HRT at some time, 50% of those with a hysterectomy only had used HRT and only 30% of women with natural menopause had used HRT.[2]

About 80% of women experience Vasomotor symptoms as they transition into menopause and according to the Study of Women's Health Across the Nation (SWAN)[3] these symptoms last average 7.4 years after menopause.

Many women opt for menopausal hormone therapy (MHT) to relieve the vasomotor symptoms, especially after the current research have shown it to be safe in women within 10 years of menopause and no contraindication. MHT have many adverse effects in older postmenopausal women (over age 60 years) and is not generally indicated.

Because of the concern for safety, many women are turning towards plant based herbal remedies often called as “Bioidentical hormones”. These are synthesized from soy and plant extract and modified to be structurally similar to endogenous hormones. A recent Systematic Review and Meta-analysis published in the recent edition of Journal of American Medical Association (JAMA)[4] sought to determine the effectiveness of these therapies in relieving vasomotor symptoms and vaginal dryness.

Two independent reviewers extracted data from Ovid MEDLINE, EMBASE, and Cochrane Central, searching for eligible studies that were published before March 27,2016. A total of 62 studies were identified, including 6653 individual women. The main outcome studied were Hot flashes, night sweats, and vaginal dryness. The time range of therapy extended between 4 weeks to 2 years, the average being about 12 weeks.

Out of 62 studies, only 36 studies used plant based phytoestrogens, the rest used other herbal and Chinese herbal medicines.

As compared to placebo use of phytoestrogen was seen to decrease number of hot flashes per day (pooled mean difference of changes -1.31, 95% CI -2.02 to -0.61) and vaginal dryness score (pooled mean difference -0.31, 95% CI -0.52 to -0.10) but no difference was seen in daily night sweat score between the two treatment regimen. 

Dr. Oscar H. Franco, MD, of Erasmus University Medical Center in Rotterdam, The Netherlands, who is the lead researcher also and colleagues also attempted to determine the individual effects of plant based treatments like all forms of soy isoflavones, Black Cohosh and Chinese and non-Chinese medicinal herbs.

Red leaf clover and soy isoflavones were not found much effective in hot flashes. No definitive evidence regarding its active ingredients and concerns over safety and side effects were also important issues regarding its use in clinical practice.

Studies including Chinese herbal medicines and other herbal remedies lacked sufficient power to perform meta- analysis but the results were inconsistent and did not show any association.

The study had several limitations including the reporting of the hot flashes being itself subjected to recall bias, methodological deficiencies, limited generalizability, and inconsistent composition of phytoestrogen used.

The authors cautioned that the results should be interpreted in light of the limitations and further rigorous well designed randomized, placebo-controlled, double-masked trial with large women from different racial/ethnic background and menopausal status that could be followed up for years is required before any conclusion can be drawn.

Current evidence does suggest that the composite and individual specific phytoestrogen use was associated with moderate reduction in night sweats and vaginal dryness but has no effect on hot flashes.




[1] http://www.menopause.org/docs/2012/cg_a.pdf?sfvrsn=2
[2] http://www.cdc.gov/nchs/data/misc/hrt_booklet.pdf
[3] http://www.swanstudy.org/
[4] http://jama.jamanetwork.com/article.aspx?articleid=2529629
[5] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566363/

Friday, January 1, 2016

Few decisive articles in gynecology from 2015



Medication approved for low sexual desire in women.

Flibanserin is the first and currently only drug approved by the US Food and Drug Administration (FDA) for female sexual dysfunction. The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is hailed by many as “Female Viagra”, but the daily dosing, severe adverse reaction when combined with alcohol, somnolence and dizziness limits its use. Also the daily dosing will only result in   modest increase in sexually satisfying event and sexual desire.


New guidelines from Bethesda for cervical screening cytology reporting.

The past decade has witnessed several changes in the realm of cervical cancer screening, prevention, and management. A new category was created as ‘ASC-H ‘which includes those Low-grade squamous intraepithelial lesion (LSIL) specimens that contain a few cells that are suspicious for but not diagnostic of high-grade squamous intraepithelial lesions (HSIL). More testing is recommended in the form of colposcopy and biopsy.
The Bethesda System 2001 for reporting cervical cytology recommends reporting benign-appearing, exfoliated endometrial cells (BEC) in women aged 40 years or older. The 2014 guidelines advocate it’s reporting only in women ≥45 years as finding of BEC was not found to be effective for predicting endometrial hyperplasia or carcinoma in women aged 40-45 yrs. 



CDC updates the guidelines on the management of sexually transmitted infections in June 2015. 

 

These updated guidelines discuss:




  • Screening recommendations for gonorrhea and chlamydia;
  • Nucleic acid amplification tests for diagnosing trichomoniasis;
  • Updated treatment for chlamydia during pregnancy;
  • Updated human papillomavirus (HPV) vaccine recommendations;
  • Alternative treatment options for genital warts;
  • The role of Mycoplasma genitalium in urethritis and cervicitis;
  • Information on the clinical care of transgender men and women.
  • Annual testing for hepatitis C in persons with HIV-infected men who have sex with men and T. vaginalis testing for HIV-infected women annually and when pregnant;
  • Updated recommendations for diagnostic evaluation of urethritis;
  • T. vaginalis retesting in women to detect repeat infection after 7 days of treatment.

Timing is important in Menopausal Hormone Therapy (MHT).


The use of MHT has been a subject of debate two decades.  However studies in 2015 and an updated version of Cochrane review that was published in 2013 lend support to the ‘timing hypothesis’, which posits that cardiovascular benefit may be derived when ET or HT is used close to the onset of menopause. It is seen in recent studies that menopausal hormone therapy (MHT) in the early menopausal years (<10 years from menopause) may not be associated with excess cardiovascular risk when compared with use in the later menopausal years.
This hypothesis was further supported by a meta-analysis of 19 trials of oral HT (which included the women’s health initiative) leading to a combined total of 40,410 post-menopausal women. These women had a lower risk of coronary heart disease (CHD) compared with placebo and a lower mortality rate. The relationship of duration of therapy to cardiovascular outcomes awaits further study. Furthermore, additional studies on progesterone versus synthetic progestins are needed.

Topical steroids confer protection against Vulvar carcinoma in women with Vulvar Lichen Sclerosus(VLS).



A prospective longitudinal cohort study conducted by a private dermatologist and gynecologist included 507 women with histologically proven VLS. The study objective was long-term preventive topical corticosteroid (TCS) treatment of VLS, with a target outcome of induction and maintenance of normal skin texture and color, reduces the risk of vulvar carcinoma, relieves symptoms, improves function, and preserves vulvar architecture, and to evaluate the adverse effects of treatment.
It was seen that women who was compliant with the treatment had a better chance of near normal cosmetic appearance, decreased risk of vulvar carcinoma. The adverse effects of corticosteroids were minimal.

References:





http://www.ncbi.nlm.nih.gov/pubmed?term=25754617